Posted by Michael Wonder on 17 Mar 2026
Sun Pharma announces US FDA acceptance of supplemental biologics license application for Ilumya (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis
16 March 2026 - Sun Pharmaceutical Industries announced that the US FDA has accepted for review the supplemental biologics license application for Ilumya for the treatment of adults with active psoriatic arthritis.
The FDA regulatory action date for this biologics license application is expected by 29 October 2026.
